Rein therapeutics announces adjournment of annual meeting of stockholders

Meeting adjourned to wednesday, july 23, 2025 at 9:00 a.m. eastern time austin, texas , june 24, 2025 /prnewswire/ -- rein therapeutics ("rein") (nasdaq: rntx), a biopharmaceutical company advancing a novel pipeline of first-in-class medications to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it adjourned, without conducting any business, the 2025 annual meeting of stockholders (the "annual meeting") on tuesday, june 24, 2025, due to the fact that a quorum was not achieved and to allow more opportunity for company stockholders to vote on all proposals described in rein's definitive proxy statement filed with the securities and exchange commission (the "sec") on may 12, 2025.
RNTX Ratings Summary
RNTX Quant Ranking